Beta Bionics, Inc.

BBNX

Beta Bionics, Inc.

BBNX

Insider Sentiment (TTM):

Last Purchase:2025-01-31Last Sale:2026-06-29Shares Purchased (TTM):0Shares Sold (TTM):179,030

Institutional Sentiment:

As of:2026-03-31Institutional Shares Owned:48,672,073Shares Outstanding:44,436,274Institutional Ownership Pct.:109.53%

Earnings Market Reaction:

Filing Date:2026-04-21Price on Filing Date:N/APrevious Close:N/A% Change:N/A

Companies in Surgical & Medical Instruments & Apparatus

SYK BSX MMM BDX IDXG MDLN

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Financial Statements

10‑Q10‑K

Values in Millions ($)	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31
Common Class A	-	-	0	0	0	0
Assets
Cash And Cash Equivalents At Carrying Value	30	32	38	35	42	30
Restricted Cash Current	0	0	-	-	-	-
Short Term Investments	169	188	190	215	189	73
Assets Current
Assets Current	248	268	270	286	262	133
Accounts Receivable Net Current	16	17	12	11	9	12
Inventory Net	24	22	20	17	16	13
Prepaid Expense And Other Assets Current	9	10	9	8	6	4
Property Plant And Equipment Net	10	9	7	6	6	5
Operating Lease Right Of Use Asset	6	7	7	6	6	7
Restricted Cash Noncurrent	-	-	0	0	0	0
Deferred Costs	-	-	-	-	-	5
Temporary Equity Carrying Amount Attributable To P…	-	-	-	-	-	321
Long Term Investments	40	45	45	31	64	-
Other Assets Noncurrent	0	0	0	0	0	0
Assets	304	329	330	330	338	150
Liabilities And Stockhold…
Liabilities
Accounts Payable Current	2	5	4	3	3	3
Accrued Liabilities And Other Liabilities	17	22	18	13	11	16
Liabilities Current
Liabilities Current	23	31	25	19	16	21
Operating Lease Liability Current	2	2	2	2	2	2
Deferred Revenue Current	2	2	1	1	1	1
Operating Lease Liability Noncurrent	5	5	6	5	5	6
Deferred Revenue Noncurrent	3	3	3	3	2	2
Other Liabilities Noncurrent	2	2	1	1	-	-
Liabilities	33	41	35	28	24	74
Common Stock Value	0	0	0	0	0	0
Additional Paid In Capital	663	657	651	644	639	51
Stockholders Equity
Stockholders Equity	271	288	295	302	314	-245
Accumulated Other Comprehensive Income Loss Net Of…	-0	0	0	0	0	0
Retained Earnings Accumulated Deficit	-392	-370	-356	-342	-325	-297
Liabilities And Stockholders Equity	304	329	330	330	338	150
Common Class B	-	4	0	-4	4	0
Common Class C	-	-	0	0	0	0
Temporary Equity Par Or Stated Value Per Share	-	0	0	0	0	0
Temporary Equity Shares Authorized	-	0	0	0	0	35
Temporary Equity Shares Issued	-	0	0	0	0	17
Temporary Equity Shares Outstanding	-	0	0	0	0	17
Temporary Equity Liquidation Preference	-	0	0	0	0	355
Preferred Stock Par Or Stated Value Per Share	-	0	0	0	0	0
Preferred Stock Shares Authorized	-	10	10	10	10	10
Preferred Stock Shares Issued	-	0	0	0	0	0
Preferred Stock Shares Outstanding	-	0	0	0	0	0
Common Stock Par Or Stated Value Per Share	0	0	0	0	0	0
Common Stock Shares Authorized	700	700	700	700	700	700
Common Stock Shares Issued	45	44	44	43	43	33
Shares Outstanding	45	44	44	43	43	33

Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables

Start free trial

Custom Table

10‑Q10‑K

0/5

Search a metric to start building a table

Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals

Start free trial

Interactive Financial Visualizations

10‑Q10‑K

Stock Price:

OnOff

Transformations:

0/1

Search a metric to start building a visual

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Earnings Market Reaction

10‑Q10‑K

Fiscal Year	Q1 1 Month	Q1 2 Month	Q1 3 Month	Q2 1 Month	Q2 2 Month	Q2 3 Month	Q3 1 Month	Q3 2 Month	Q3 3 Month	Q4 1 Month	Q4 2 Month	Q4 3 Month
2026	-22.90%	18.42%	38.79%	-	-	-	-	-	-	-	-	-
2025	51.89%	32.78%	30.75%	16.30%	53.21%	36.56%	29.41%	20.47%	-23.81%	-20.09%	-3.06%	-29.35%
2024	-	-	-	-	-	-	-	-	-	-26.81%	-5.65%	25.43%
Data beyond 3 years is for subscribers only. Unlock 17+ years of financial data Start 7-day free trial

Subscribe to unlock 17+ years of financial data and 50+ calculated metrics

Start 7-day free trial

Subscribe to unlock 17+ years of data and 50+ calculated metrics

Start free trial

Performance and Valuation Metrics

Metrics	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31
Liquidity Ratios
Current Ratio	10.69	8.66	10.64	14.68	15.88	6.29
Quick Ratio	9.29	7.64	9.46	13.40	14.58	5.46
Working Capital	224.80M	236.98M	244.64M	266.59M	245.42M	111.78M
Leverage & Debt
Debt to Equity	0.12	0.14	0.12	0.09	0.08	-0.30
Debt Ratio	0.11	0.13	0.11	0.09	0.07	0.49
Efficiency & Turnover
Asset Turnover TTM	0.34	0.42	0.21	-	-	-
Days Sales Outstanding TTM	41.07	53.00	61.82	-	-	-
Receivables Turnover TTM	8.89	6.89	5.90	-	-	-
Per Share Metrics
Diluted EPS TTM	-1.50	-1.81	-1.37	-	-	-
Free Cash Flow Per Share TTM	-1.38	-1.39	-1.05	-	-	-
Dividend Per Share TTM	0.00	0.00	0.00	-	-	-
Margin Metrics
Gross Profit Margin TTM	57.15%	55.40%	-	-	-	-
Operating Profit Margin TTM	-70.13%	-71.50%	-81.55%	-	-	-
Net Profit Margin TTM	-60.27%	-73.02%	-87.68%	-	-	-
Valuation Metrics
P/E TTM	-6.70	-16.87	-14.51	-	-	-
P/B TTM	1.64	4.29	2.94	2.09	1.20	-
P/S TTM	4.04	12.32	12.73	-	-	-
Market Cap	445.25M	1.23B	867.01M	631.77M	375.95M	-
Enterprise Value	415.05M	1.20B	828.42M	596.69M	333.39M	-
Calculated Values
Free Cash Flow TTM	-61.12M	-56.22M	-45.69M	-	-	-
Net Debt	-30.21M	-31.68M	-38.59M	-35.08M	-42.55M	-30.53M
Per-Share and Margin
EPS TTM
Adjusted EPS TTM
Cash Flow Per Share TTM
Pretax Margin TTM
Stock Comp to Revenue TTM
Turnover Ratios and Averages
Average Assets
Average Equity
Average Inventory
Average Receivables
Average Accounts Payables
Inventory Turnover TTM
Payables Turnover TTM
Days Inventory Outstanding TTM
Days Payables Outstanding TTM
Cash Conversion Cycle TTM
Working Capital to Revenue
Deferred Revenue to Revenue
Growth Rates
Total Assets Growth (1Y)
Total Assets Growth (3Y)
Total Assets Growth (5Y)
Dividends Paid Growth (1Y)
Dividends Paid Growth (3Y)
Dividends Paid Growth (5Y)
EPS Growth (3Y)
EPS Growth (5Y)
Net Income Growth (3Y)
Net Income Growth (5Y)
Net Profit Margin Growth (1Y)
Net Profit Margin Growth (3Y)
Net Profit Margin Growth (5Y)
Net Revenue Growth (3Y)
Net Revenue Growth (5Y)
Deferred Revenue Growth (1Y)
Retained Earnings Growth (1Y)
Credit, Liquidity, Returns, Payout
Cash Ratio
Net Working Capital
Debt to EBITDA TTM
Net Debt to EBITDA TTM
Net Debt to Equity
Altman A
Altman B
Altman C
Altman D
Altman E
Altman Z-Score
ROA TTM
ROE TTM
NOPAT TTM
ROIC TTM
Effective Tax Rate TTM
Payout Ratio TTM
Dilution Ratio
Retained Earnings to Equity
Treasury Stock to Equity
Treasury Stock Change (1Y)
Accrued to Current Liabilities
Valuation Ratios
P/CF TTM
Dividend Yield TTM
Free Cash Flow Yield TTM
EV EBITDA TTM
EV EBIT TTM
Stock Compensation TTM
Adjusted Net Income TTM
Billings TTM
Total Debt
Invested Capital

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Insider Transactions

2026-06-29Sale

Owner: Feider, Stephen

Title: Chief Financial Officer

Shares: 4,896

Price/Share: $17.03

Value: $83,378.88

Shares Owned: 165,931

Relationship: Officer

Ownership: Direct

2026-06-24Sale

Owner: Jones, Christy

Title: -

Shares: 1,406

Price/Share: $15.00

Value: $21,090.00

Shares Owned: 25,994

Relationship: Director

Ownership: Direct

2026-06-24Sale

Owner: Hopman, Mark

Title: Chief Commercial Officer

Shares: 1,258

Price/Share: $15.01

Value: $18,882.58

Shares Owned: 129,354

Relationship: Officer

Ownership: Direct

2026-06-04Sale

Owner: Hopman, Mark

Title: Chief Commercial Officer

Shares: 275

Price/Share: $12.31

Value: $3,385.25

Shares Owned: 130,612

Relationship: Officer

Ownership: Direct

2026-06-04Sale

Owner: Jones, Christy

Title: -

Shares: 2,811

Price/Share: $14.00

Value: $39,354.00

Shares Owned: 27,400

Relationship: Director

Ownership: Direct

Filed Date	Owner	Relationship	Title	Ownership	Purchase/Sale	No. Shares	Price Per Share	Value	Shares Owned	Document Type
2026-06-29	Feider, Stephen	Officer	Chief Financial Officer	Direct	Sale	4,896	17.03	$83,378.88	165,931	4
2026-06-24	Jones, Christy	Director	-	Direct	Sale	1,406	15.00	$21,090.00	25,994	4
2026-06-24	Hopman, Mark	Officer	Chief Commercial Officer	Direct	Sale	1,258	15.01	$18,882.58	129,354	4
2026-06-04	Hopman, Mark	Officer	Chief Commercial Officer	Direct	Sale	275	12.31	$3,385.25	130,612	4
2026-06-04	Jones, Christy	Director	-	Direct	Sale	2,811	14.00	$39,354.00	27,400	4
2026-06-02	Mensinger, Mike	Officer	Chief Product Officer	Direct	Sale	4,378	12.61	$55,206.58	184,415	4
2026-06-02	Russell, Steven Jon	Officer	Chief Medical Officer	Direct	Sale	4,222	12.61	$53,239.42	173,849	4
2026-06-02	Hopman, Mark	Officer	Chief Commercial Officer	Direct	Sale	5,329	12.61	$67,198.69	130,887	4
2026-06-02	Saint, Sean	Director,Officer	President & CEO	Direct	Sale	16,872	12.61	$212,755.92	420,937	4
2026-06-02	Feider, Stephen	Officer	Chief Financial Officer	Direct	Sale	6,676	12.61	$84,184.36	166,053	4
2026-05-21	Jones, Christy	Director	-	Direct	Sale	1,998	9.95	$19,880.10	13,246	4
2026-05-21	Lezack, Adam	Director	-	Direct	Sale	1,000	9.95	$9,950.00	11,432	4
2026-03-04	Hopman, Mark	Officer	Chief Commercial Officer	Direct	Sale	353	11.57	$4,084.21	139,133	4
2026-03-02	Saint, Sean	Director,Officer	President & CEO	Direct	Sale	3,384	12.36	$41,826.24	437,809	4
2026-03-02	Mensinger, Mike	Officer	Chief Product Officer	Direct	Sale	1,064	12.36	$13,151.04	188,793	4
2026-03-02	Feider, Stephen	Officer	Chief Financial Officer	Direct	Sale	1,428	12.36	$17,650.08	172,729	4
2026-03-02	Hopman, Mark	Officer	Chief Commercial Officer	Direct	Sale	834	12.36	$10,308.24	139,486	4
2026-03-02	Russell, Steven Jon	Officer	Chief Medical Officer	Direct	Sale	1,026	12.36	$12,681.36	179,096	4
2026-01-06	Mensinger, Mike	Officer	Chief Product Officer	Direct	Sale	2,200	30.10	$66,220.00	80,752	4
2026-01-02	Feider, Stephen	Officer	Chief Financial Officer	Direct	Sale	20,000	29.53	$590,600.00	42,614	4
2026-01-02	Mensinger, Mike	Officer	Chief Product Officer	Direct	Sale	7,800	29.88	$233,064.00	82,952	4
2025-12-04	Hopman, Mark	Officer	Chief Commercial Officer	Direct	Sale	2,061	30.66	$63,190.26	136,216	4
2025-12-02	Russell, Steven Jon	Officer	Chief Medical Officer	Direct	Sale	1,025	29.34	$30,073.50	178,071	4
2025-12-02	Feider, Stephen	Officer	Chief Financial Officer	Direct	Sale	1,427	29.34	$41,868.18	42,614	4
2025-12-02	Mensinger, Mike	Officer	Chief Product Officer	Direct	Sale	1,063	29.34	$31,188.42	90,752	4
2025-12-02	Saint, Sean	Director,Officer	President & CEO	Direct	Sale	3,278	29.34	$96,176.52	97,924	4
2025-12-01	Palasis, Maria	Director	-	Direct	Sale	1,406	29.64	$41,673.84	8,435	4
2025-12-01	Lezack, Adam	Director	-	Direct	Sale	1,406	29.63	$41,659.78	8,435	4
2025-10-31	Palasis, Maria	Director	-	Direct	Sale	1,406	27.16	$38,186.96	9,841	4
2025-10-31	Lezack, Adam	Director	-	Direct	Sale	1,406	27.28	$38,355.68	9,841	4
2025-10-03	Feider, Stephen	Officer	Chief Financial Officer	Direct	Sale	4,982	21.90	$109,105.80	44,041	4
2025-10-01	Feider, Stephen	Officer	Chief Financial Officer	Direct	Sale	15,018	20.92	$314,176.56	44,041	4
2025-09-08	Feider, Stephen	Officer	Chief Financial Officer	Direct	Sale	9,900	21.13	$209,187.00	44,041	4
2025-09-05	Hopman, Mark	Officer	Chief Commercial Officer	Direct	Sale	11,411	20.56	$234,610.16	31,215	4
2025-09-05	Feider, Stephen	Officer	Chief Financial Officer	Direct	Sale	100	21.00	$2,100.00	44,041	4
2025-09-02	Hopman, Mark	Officer	Chief Commercial Officer	Direct	Sale	848	18.86	$15,993.28	33,284	4
2025-09-02	Saint, Sean	Director,Officer	President & CEO	Direct	Sale	3,359	18.86	$63,350.74	101,202	4
2025-09-02	Feider, Stephen	Officer	Chief Financial Officer	Direct	Sale	1,462	18.86	$27,573.32	44,041	4
2025-09-02	Mensinger, Mike	Officer	Chief Product Officer	Direct	Sale	1,089	18.86	$20,538.54	91,815	4
2025-09-02	Russell, Steven Jon	Officer	Chief Medical Officer	Direct	Sale	1,015	18.86	$19,142.90	71,017	4
2025-08-22	Feider, Stephen	Officer	Chief Financial Officer	Direct	Sale	4,413	17.01	$75,065.13	45,503	4
2025-08-19	Feider, Stephen	Officer	Chief Financial Officer	Direct	Sale	5,587	17.03	$95,146.61	45,503	4
2025-08-19	Hopman, Mark	Officer	Chief Commercial Officer	Direct	Sale	16,158	16.61	$268,384.38	34,132	4
2025-06-02	Russell, Steven Jon	Officer	Chief Medical Officer	Direct	Sale	1,039	17.96	$18,660.44	72,032	4
2025-06-02	Hopman, Mark	Officer	Chief Commercial Officer	Direct	Sale	868	17.96	$15,589.28	34,132	4
2025-06-02	Mensinger, Mike	Officer	Chief Product Officer	Direct	Sale	1,115	17.96	$20,025.40	92,904	4
2025-06-02	Feider, Stephen	Officer	Chief Financial Officer	Direct	Sale	1,497	17.96	$26,886.12	45,503	4
2025-06-02	Saint, Sean	Director,Officer	President & CEO	Direct	Sale	3,439	17.96	$61,764.44	104,561	4
2025-01-31	Mensinger, Mike	Officer	Chief Product Officer	Direct	Purchase	33,350	17.00	$566,950.00	59,019	4
2025-01-31	Mensinger, Mike	Officer	Chief Product Officer	Direct	Sale	13	17.00	$221.00	25,669	4
2025-01-31	Wellington, Hadley Harbor…	TenPercentOwner	-	Direct	Purchase	1,000,000	17.00	$17,000,000.00	3,901,599	4
Data beyond 3 years is for subscribers only. Unlock 17+ years of financial data Start 7-day free trial

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Institutional Ownership

No data available for chart

2026-03-31

109.53%

Inst. Shares: 48,672,073

Shares Outstanding: 44,436,274

2025-12-31

113.06%

Inst. Shares: 45,821,883

Shares Outstanding: 40,529,051

2025-09-30

108.56%

Inst. Shares: 47,367,210

Shares Outstanding: 43,634,006

2025-06-30

101.60%

Inst. Shares: 44,083,872

Shares Outstanding: 43,390,652

2025-03-31

134.89%

Inst. Shares: 41,429,997

Shares Outstanding: 30,714,769

Date	Institutional Shares Owned	Shares Outstanding	Institutional Ownership %
2026-03-31	48,672,073	44,436,274	109.53%
2025-12-31	45,821,883	40,529,051	113.06%
2025-09-30	47,367,210	43,634,006	108.56%
2025-06-30	44,083,872	43,390,652	101.60%
2025-03-31	41,429,997	30,714,769	134.89%
Data beyond 3 years is for subscribers only. Unlock 17+ years of financial data Start 7-day free trial

Beta Bionics, Inc. (BBNX) — SEC Financial Statements & Analysis

Beta Bionics, Inc. (BBNX) is a surgical & medical instruments & apparatus company, incorporated in DE. Beta Bionics, Inc. trades on Nasdaq as: BBNX. Based on its latest SEC filing (Form 10-Q, period ending 2026-03-31), Beta Bionics, Inc. reported a Gross Profit Margin of 57.15% (TTM), a Debt-to-Equity ratio of 0.12x, a Price-to-Sales (P/S) ratio of 4.04x (TTM), a Price-to-Book (P/B) ratio of 1.64 (TTM), at a market cap of $445.25M. Figures below are sourced from SEC EDGAR, as-filed.

Gross Profit Margin TTM: 57.15%
Debt To Equity: 0.12x
P/S TTM: 4.04x
P/B TTM: 1.64
Market Cap: $445.25M

Data as of 2026-03-31 · Source: SEC EDGAR

Frequently Asked Questions

What industry is Beta Bionics, Inc. in?

Beta Bionics, Inc. (BBNX) operates in the Surgical & Medical Instruments & Apparatus industry.

What is BBNX's market cap?

Beta Bionics, Inc. (BBNX) has a market capitalization of $445.25M as of 2026-03-31.

What exchange does BBNX trade on?

Beta Bionics, Inc. (BBNX) trades on the Nasdaq.

Where is Beta Bionics, Inc. incorporated?

Beta Bionics, Inc. is incorporated in DE.

Beta Bionics, Inc. (BBNX) — SEC Financial Statements & Analysis

Frequently Asked Questions

Research Faster.Invest Smarter.

Research Faster.
Invest Smarter.